- Home
- PWM vs SYBX Comparison
PWM vs SYBX Comparison
Compare PWM & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PWM
- SYBX
- Stock Information
- Founded
- PWM 2018
- SYBX N/A
- Country
- PWM Hong Kong
- SYBX United States
- Employees
- PWM N/A
- SYBX N/A
- Industry
- PWM
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- PWM
- SYBX Health Care
- Exchange
- PWM Nasdaq
- SYBX Nasdaq
- Market Cap
- PWM 12.4M
- SYBX 13.9M
- IPO Year
- PWM 2023
- SYBX N/A
- Fundamental
- Price
- PWM $0.40
- SYBX $1.56
- Analyst Decision
- PWM
- SYBX
- Analyst Count
- PWM 0
- SYBX 0
- Target Price
- PWM N/A
- SYBX N/A
- AVG Volume (30 Days)
- PWM 6.3M
- SYBX 79.0K
- Earning Date
- PWM 07-29-2025
- SYBX 08-07-2025
- Dividend Yield
- PWM N/A
- SYBX N/A
- EPS Growth
- PWM N/A
- SYBX N/A
- EPS
- PWM N/A
- SYBX 0.21
- Revenue
- PWM $639,912.00
- SYBX N/A
- Revenue This Year
- PWM N/A
- SYBX N/A
- Revenue Next Year
- PWM N/A
- SYBX N/A
- P/E Ratio
- PWM N/A
- SYBX $7.99
- Revenue Growth
- PWM 83.60
- SYBX N/A
- 52 Week Low
- PWM $0.31
- SYBX $0.90
- 52 Week High
- PWM $2.70
- SYBX $1.96
- Technical
- Relative Strength Index (RSI)
- PWM 50.05
- SYBX 72.23
- Support Level
- PWM $0.38
- SYBX $1.62
- Resistance Level
- PWM $0.43
- SYBX $1.96
- Average True Range (ATR)
- PWM 0.04
- SYBX 0.14
- MACD
- PWM -0.00
- SYBX 0.05
- Stochastic Oscillator
- PWM 42.17
- SYBX 60.26
About PWM Prestige Wealth Inc.
Prestige Wealth Inc is engaged in providing private wealth management services and asset management to high-net-worth and ultra-high-net-worth individuals and enterprises through its subsidiaries.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.